Condition
Bioavailability Study
Total Trials
5
Recruiting
0
Active
0
Completed
4
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 5 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 4 completed with results
Key Signals
100% success
Data Visualizations
Phase Distribution
5Total
Not Applicable (1)
P 1 (4)
Trial Status
Completed4
Withdrawn1
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 4 completed trials
Clinical Trials (5)
Showing 5 of 5 trials
NCT06773767Phase 1Completed
Bioavailability of Trazodone Hydrochloride (New Polymer) vs. Trazodone Hydrochloride Contramid® at Steady-state.
NCT02883439Not ApplicableWithdrawnPrimary
Study to Analyse Difference in Bioavailability Between MP29-02 and Fluticasone Propionate
NCT04688008Phase 1CompletedPrimary
Relative Bioavailability of Early Phase and Late Phase Hetrombopag Olamine Formulations
NCT03334084Phase 1CompletedPrimary
A Study to Compare the PK, PD and Safety and Tolerability of a SC With an IV Formulation of ARGX-113 in Healthy Male Subjects
NCT03972462Phase 1CompletedPrimary
NPC-12G Gel 0.2% Sirolimus PK Bridging Study
Showing all 5 trials